Dev Developer GSK - Search News

GSK, Nuvalent

GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover

LONDON, June 9 (Reuters) - GSK (GSK.L) has agreed to buy U.S.-listed cancer drug developer Nuvalent (NUVL.O) for $10.6 billion in its largest deal in more than a decade, marking a strategic shift und...

C&EN · 1d

GSK to buy cancer drug developer Nuvalent for $10.6 billion

· 1d · on MSN

GSK makes its biggest bet in more than a decade, paying $10.6 billion for cancer drug developer Nuvalent

· 14h

UK's FTSE 100 hits over three-week low as banks, energy stocks sag

Britain's blue-chip FTSE 100 hit its lowest since mid-May on Tuesday, bogged down by losses in heavyweight lenders HSBC and Standard Chartered, while energy giants also lost ‌ground amid declining oi...

· 14h

GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm

· 1d

GSK acquires Nuvalent for $10.6 billion in oncology push

1don MSN

GSK to buy Nuvalent for $10.6 billion in oncology push

The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.

Devdiscourse

GSK's Ambitious Move Weighs on FTSE 100

The FTSE 100 index dropped by 0.3% on Tuesday, primarily influenced by GSK's decision to acquire U.S.-based drug developer Nuvalent for $10.6 billion. The acquisition is part of GSK's strategy to enhance its lung cancer treatment portfolio.